Read more stories about
Montana Biotech >>

MATR Sponsor:

MATR Supporters:

Glaxo and J&J's New €150MM Fund Will Help the Biotech Ecosystem

March 26, 2012View for printing

Index Ventures made news recently when it announced a new €150 million fund to invest in early-stage, life science companies. With many venture firms scaling back or exiting the business entirely, any successful fundraising is good news. However, two aspects made the announcement from Index particularly noteworthy: first, the fund is focused on early-stage innovation, a segment largely shunned by traditional VCs and, second, two of the industry's largest firms - Janssen and GlaxoSmithKline - agreed to throw their considerable weight behind the Index team.

Troy Wilson

Full Story: ... edium=email
No reader comments so far. Be the first to comment by clicking the button below.

Reprinted under the Fair Use doctrine of international copyright law. Full copyright retained by the original publication. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

E-mail this page to a friend!